Title
LCZ696 (sacubitril/valsartan) for patients with heart failure
Date Issued
14 January 2020
Access level
open access
Resource Type
journal article
Author(s)
University of Connecticut
Publisher(s)
John Wiley and Sons Ltd
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.
Volume
2020
Issue
1
Language
English
OCDE Knowledge area
Sistema cardiaco, Sistema cardiovascular
Scopus EID
2-s2.0-85088244906
Source
Cochrane Database of Systematic Reviews
ISSN of the container
1469493X
Sponsor(s)
Contact Editor: Nikolaos Papageorgiou (St Bartholomew's Hospital, London, UK) Peer reviewers: Andrew Kompa (Monash University, Melbourne, Australia), Andrew J Sauer, MD (Associate Professor, The University of Kansas Medical Center, Kansas City, US), Francois Roubille (Cardiology Department, University of Montpellier, Montpellier, France), Dr Pardeep S Jhund (Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK)
Sources of information:
Directorio de Producción Científica
Scopus